权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Monitoring Disease in Lupus

监测狼疮疾病

基本信息

批准号：
10583454
负责人：
CHANDRA MOHAN
金额：
$ 54.2万
依托单位：
UNIVERSITY OF HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-03-08 至 2025-02-28
项目状态：
未结题

项目摘要

Lupus is a systemic autoimmune disease resulting in inflammation in multiple organ systems. The disease course is very variable and unpredictable. There is a definite clinical need for better biomarkers for monitoring this disease, particularly renal disease. The current tools available for monitoring lupus and end-organ involvement are not optimal. More reliable tools that detect early disease are warranted. Early detection and prompt treatment can have significant impact on morbidity and disease course. There is also a need for better biomarkers that can be used to assess treatment response in clinical trials. Our completed studies using a couple of targeted proteomic platforms have uncovered several serum or urine proteins that are elevated in lupus patients with elevated SLE disease activity index. From our completed studies, and newly proposed targeted proteomic screens, we will assemble a panel of about 40 serum or urine biomarkers. We will ascertain if these novel biomarkers have the potential to identify lupus patients with active renal disease, monitor disease activity serially, predict treatment response or project long-term outcome in these patients. Besides their biomarker potential, the protein markers examined in this proposal may also constitute therapeutic targets as they exhibit a variety of interesting functional attributes. Better non-invasive biomarkers can significantly improve disease management in patients with lupus nephritis.

狼疮是一种全身性自身免疫性疾病，会导致多个器官系统的炎症。这种病航向是非常多变和不可预测的。临床上确实需要更好的生物标志物来进行监测。这种疾病，尤其是肾脏疾病。目前可用于监测狼疮和终末器官的工具参与并不是最理想的。需要更可靠的工具来检测早期疾病。早期发现和及时治疗可以对发病率和病程产生重大影响。还需要更好的在临床试验中可用于评估治疗反应的生物标志物。我们完成的研究使用的是几个靶向蛋白质组平台已经发现了几种血清或尿蛋白，它们在 SLE疾病活动指数升高的狼疮患者。根据我们已完成的研究，和新提出的针对蛋白质组筛选，我们将组装一个由大约40个血清或尿液生物标记物组成的小组。我们会确定如果这些新的生物标记物有可能识别患有活动性肾脏疾病的狼疮患者，监测疾病连续活动，预测治疗反应或预测这些患者的长期结果。除了他们的生物标记物的潜力，本提案中检查的蛋白质标记物也可能构成治疗靶点，如它们展示了各种有趣的功能属性。更好的非侵入性生物标志物可以显著改善狼疮性肾炎患者的疾病管理。